ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GSK will pay Mersana Therapeutics, an antibody-drug conjugate (ADC) specialist, $100 million for the option to codevelop and commercialize XMT-2056, an ADC that targets the protein HER2. Mersana intends to test the drug in Phase 1 trials against several types of HER2-expressing tumors such as breast, gastric, and non-small-cell lung cancers, the companies say. Mersana is eligible to receive up to $1.36 billion in further payments if GSK exercises its option.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter